LEKTI domain 6 displays anti-inflammatory action in vitro and in a murine atopic dermatitis model.
Authors
Canbolat P, Wilzopolski J, Kaessmeyer S, Filor V, Vidak J, Rüger M, Mägert HJ, Forssmann WG, Bäumer W
Abstract
Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a serine protease inhibitor consisting of multiple domains. A loss of function mutation is described in Netherton patients that show severe symptoms of atopic lesions and itch.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
